EFPIA Response To The A (H1N1) Novel Influenza Virus

Main Category: Flu / Cold / SARS
Also Included In: Bird Flu / Avian Flu;  Infectious Diseases / Bacteria / Viruses;  Immune System / Vaccines
Article Date: 05 May 2009 - 8:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

EFPIA is aware and concerned by the current outbreak of a novel influenza, which appears to have originated in Mexico. We note the WHO's decision to raise the level of influenza pandemic alert from the current phase 4 to phase 5. We will continue to monitor the situation closely, working with our colleagues at the International Federation of Pharmaceutical manufacturers and Associations.

Concerns in recent years over the possibility of pandemic avian influenza have meant that both governments and manufacturers have planned for such an eventuality. Therefore we are confident that our members are ready and well prepared to respond rapidly and provide their expertise in dealing with the changing demands of this situation. We are ready to work with governments and public health authorities to provide whatever support may be required.

EFPIA members involved in the manufacture of influenza vaccines and antiviral treatments are already in contact with the relevant authorities. They will provide all necessary, expertise assistance and capacity required to ensure the rapid development of a vaccine effective against the A (H1N1) strain. They will also be meeting with the government bodies at European and Member State levels to determine what assistance they can provide.

The European Vaccine Manufacturers Association, along with antiviral manufacturers, has already met with the European Commission to discuss the situation. The Commission and the industry have examined technical and regulatory issues around speeding production of effective vaccines, and will continue to work together to reduce any impact and spread of the virus.

Brian AGER
European Federation of Pharmaceutical industries and Associations